Search

Author/Creator Cappuzzo, F

1. 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. (15th December 2019)

Authors:
Reck, M; Cappuzzo, F; Rodriguez-Abreu, D; Cho, D C; Schwarz, J K; Riese, M J; Gupta, A; Chan, T; Saab, R; Singel, S; Lin, W; Tagliaferri, M; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1818TiPMulticentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. (23rd October 2018)

Authors:
Pagano, M; Zanelli, F; Gnoni, R; Bonelli, C; Tiseo, M; Boni, L; Ceresoli, G L; Zucali, P A; Grosso, F; Pasello, G; Cappuzzo, F; Pinto, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Issue 12 (December 2022)

Authors:
Del Mastro, Lucia; Poggio, Francesca; Blondeaux, Eva; De Placido, Sabino; Giuliano, Mario; Forestieri, Valeria; De Laurentiis, Michelino; Gravina, Adriano; Bisagni, Giancarlo; Rimanti, Anita; Turletti, Anna; Nisticò, Cecilia; Vaccaro, Angela; Cognetti, Francesco; Fabi, Alessandra; Gasparro, Simon...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 12(2022)
Page Start:
1571
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018)

Authors:
Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Archer, V; Ochi Lohmann, T; Wang, L; Kowanetz, M; Lin, W; Sandler, A; West, H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA9IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (25th November 2018)

Authors:
Mok, T S K; Socinski, M A; Reck, M; Jotte, R M; Lim, D W-T; Cappuzzo, F; Orlandi, F J; Stroyakovskiy, D; Nogami, N; Rodríguez-Abreu, D; Moro-Siblot, D; Thomas, C A; Barlesi, F; Finley, G; Lee, A; Shankar, G; Yu, W; Kowanetz, M; Lin, W; Nishio, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P-318The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study. (2nd July 2019)

Authors:
D'Arcangelo, M; Buonerba, C; Avallone, A; Dazzi, C; Frassineti, G; Tamberi, S; Tassinari, D; Aprile, G; Granetto, C; Bonetti, A; Vecchiarelli, S; Cappuzzo, F
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗